Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma - Summary - MDSpire
Advertisement
Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma
To compare the efficacy and safety of immunotherapy combined with induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemoradiotherapy with cisplatin versus induction chemotherapy followed by two cycles of concurrent chemoradiotherapy with cisplatin in patients with locally advanced nasopharyngeal carcinoma.
Key Findings:
29.4% of patients in the immunochemotherapy group achieved complete remission compared to 14.3% in the IC-CCRT group (p=0.02).
Recurrence or metastasis occurred in 7.4% of the immunochemotherapy group versus 19.0% in the IC-CCRT group.
2-year event-free survival (EFS) was 93.5% in the immunochemotherapy group versus 81.1% in the IC-CCRT group (p=0.03).
Overall survival (OS) was 100.0% in the immunochemotherapy group versus 97.9% in the IC-CCRT group (p=0.3).
Grade 3–4 acute adverse events were reported in 41.1% of the immunochemotherapy group and 55.2% of the IC-CCRT group.
Interpretation:
Remove unsupported conclusions.
Limitations:
The study is retrospective and may be subject to selection bias.
Data requires confirmation through prospective randomized controlled studies.
